logo
Tornado Cash was a 'giant washing machine' for North Korea's dirty crypto, feds tell Roman Storm jury

Tornado Cash was a 'giant washing machine' for North Korea's dirty crypto, feds tell Roman Storm jury

Yahoo15-07-2025
Tornado Cash developer Roman Storm is on trial for a $1B crypto-laundering conspiracy.
Prosecutors say Tornado Cash was the go-to anonymizing tool for hackers and scammers.
Storm brazenly wore a shirt featuring the Tornado Cash logo and a washing machine, prosecutors said.
Is Tornado Cash developer Roman Storm just a smart and selfless software engineer? Or is the 34-year-old Russian expat the go-to money launderer for the world's biggest scammers and hackers?
A federal jury in Manhattan heard two very different stories in opening statements Tuesday for Storm's $1 billion money laundering conspiracy trial.
Prosecutors pointed to three of the biggest crypto heists in recent years — including North Korea's $600 million hack attack on the online gaming platform Axie Infinity.
Each time, the criminals hid their stolen money by running it through Tornado Cash, prosecutor Special US Attorney Kevin Gerard Mosley told the seven-woman, five-man jury.
Storm's popular online tool "mixes" cryptocurrency, scrambling transactions to make them "basically untraceable and virtually impossible for law enforcement or anyone else to track," Mosley told the jury.
"The defendant was running and profiting from a giant washing machine for dirty money, and he knew it," the prosecutor said.
"He even marketed Tornado Cash as a washing machine," he added. "In fact," he promised jurors, "you will see a photo of the defendant wearing a T-shirt showing a washing machine with the Tornado Cash logo on it."
Prosecutors say Storm kept laundering hundreds of millions of dollars for hackers with the North Korea-linked Lazarus Group even after such transactions were banned under US and global sanctions.
"Criminals could avoid being tracked by running their money through the defendant's washing machine," Mosley said of Tornado Cash, a so-called crypto "mixing" tool that lets users deposit and withdraw crypto from a shared pool, obscuring the identities on either end of the transaction.
"It would be mixed up with other crypto," Mosley said of the hackers' criminal proceeds, "so it would come out looking clean."
Storm tried to cover his tracks after the Lazarus Group was sanctioned, the prosecutor said, by removing a single software control "switch" that could be used to shut off just one part of the washing machine.
"He did that so he could pretend the whole washing machine was out of his control," while continuing to reap millions in profits, the prosecutor said.
But in fact, Storm was still "running the whole laundromat," he added.
"He had the keys to the front door, he paid the gas and electric bills, he still said, 'We're open for business.'"
In her own opening statement, defense attorney Keri Curtis Axel countered that Storm is just a privacy advocate who wrote some very useful code.
Tornado Cash was backed by US investors, and was built for perfectly legitimate purposes, she told the jury.
"Roman had nothing to do with the hackers and scammers — he didn't want them to use Tornado Cash," she said.
"The overwhelming majority of people who used it were normal people using it for their own financial privacy, which is the purpose that Roman intended."
As for that T-shirt? The one with the Tornado Cash logo imposed over a washing machine?
"He wore it at a reputable tech conference in Boston in 2019," Axel said. "And people of the jury, I want you to keep in mind it's just a T-shirt — worn in poor taste."
"It's like a comic strip or a meme. It was a joke," she said. "It was not evidence of a crime."
The trial is expected to last about a month and to feature both hackers and victims among the government's witnesses. Storm faces up to 40 years in prison if convicted of conspiring to commit money laundering, run an unlicensed money-transmitting company, and violate federal sanctions.
Read the original article on Business Insider
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What Makes Eli Lilly and Company (LLY) a Lucrative Investment?
What Makes Eli Lilly and Company (LLY) a Lucrative Investment?

Yahoo

time12 minutes ago

  • Yahoo

What Makes Eli Lilly and Company (LLY) a Lucrative Investment?

Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company headquartered in Indianapolis, Indiana. The one-month return of Eli Lilly and Company (NYSE:LLY) was -2.64%, and its shares lost 5.52% of their value over the last 52 weeks. On July 30, 2025, Eli Lilly and Company (NYSE:LLY) stock closed at $760.08 per share, with a market capitalization of $682.351 billion. Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its second quarter 2025 investor letter: "We added to our position in Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company best known for developing and selling GLP-1 medications for diabetes and obesity. The most recent generation of GLP-1 drugs (brand names Mounjaro and Zepbound) not only offer superb blood sugar control for diabetics, but also can drive 20% or greater weight loss and likely improve cardiovascular outcomes in both diabetic and non-diabetic obese patients. We think these drugs will become the standard of care for both diabetes and obesity, and will become a $150 billion category. We see Lilly as the leader in the space, setting a high efficacy bar with their GLP-1s on the market and continuing to innovate and develop next-generation medications that are more effective and more convenient. We are excited about once-daily oral orforglipron, which recently showed Phase 3 data in type 2 diabetes that rivaled Novo Nordisk's injectable Ozempic. We expect Phase 3 orforglipron in obesity this summer to also be competitive with Novo Nordisk's injectable Wegovy. Beyond orforglipron, Lilly is also studying a high efficacy injectable (retatrutide) in Phase 3, an amylin hormone analogue (eloralintide) that can be combined with Zepbound in Phase 2, and a muscle preserving drug bimagrumab (which can also be combined with Zepbound) in Phase 2. We continue to think this market is in the early innings of uptake, we think the adoption of GLP-1s will drive Lilly to triple its total revenues by 2030, and we think Lilly has the pipeline portfolio of drugs to sustain its leadership position." Eli Lilly and Company (NYSE:LLY) is in 21st position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the first quarter, which was 115 in the previous quarter. Eli Lilly and Company (NYSE:LLY) reported strong results in first quarter of 2025, with revenue increasing 45% compared to Q1 2024. While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Eli Lilly and Company (NYSE:LLY) and shared the list of stocks Jim Cramer recently discussed. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges
Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges

Yahoo

time12 minutes ago

  • Yahoo

Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges

Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was 4.58%, and its shares gained 22.08% of their value over the last 52 weeks. On July 30, 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock closed at $572.09 per share, with a market capitalization of $46.009 billion. Baron Health Care Fund stated the following regarding IDEXX Laboratories, Inc. (NASDAQ:IDXX) in its second quarter 2025 investor letter: "Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to performance for the quarter after reporting better than-expected financial results. Foot traffic to veterinary clinics in the U.S. remains under pressure, which has continued to hamper aggregate revenue growth. Despite macroeconomic challenges, IDEXX's excellent execution has enabled the company to maintain strong performance. We believe competitive trends are outstanding, and we expect new proprietary innovations and field sales force expansion to be meaningful contributors to growth in 2025. We see increasing evidence that long-term secular trends around pet ownership and pet care spending have structurally accelerated, which should help support IDEXX's long-term growth rate." A veterinarian in a veterinary clinic examining a companion animal. IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) at the end of the first quarter, which was 58 in the previous quarter. In the first quarter of 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported organic revenue growth of 5% driven by 4.5% organic revenue gains in the CAG business, 7% organic growth in water, and 4% organic growth in LPD. While we acknowledge the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered IDEXX Laboratories, Inc. (NASDAQ:IDXX) and shared the list of best stocks to buy according to Brasada Capital Management. In Q2 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to Conestoga Capital Advisors' performance. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here's Why
Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here's Why

Yahoo

time12 minutes ago

  • Yahoo

Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here's Why

Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) offers products and technologies for structural heart disease and critical care monitoring. The one-month return of Edwards Lifesciences Corporation (NYSE:EW) was 5.69%, and its shares gained 31.20% of their value over the last 52 weeks. On July 30, 2025, Edwards Lifesciences Corporation (NYSE:EW) stock closed at $81.16 per share, with a market capitalization of $47.608 billion. Baron Health Care Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its second quarter 2025 investor letter: "We reacquired shares of Edwards Lifesciences Corporation (NYSE:EW), a leading manufacturer of heart valve replacement and repair products. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to treat aortic stenosis, a disease that obstructs the flow of blood out of the aortic valve, which strains the heart. Edwards Lifesciences has a leading position in the TAVR market backed by a robust body of clinical evidence and physician familiarity with the product and workflow. TAVR is a $5 billion market that still continues to grow many years after Edwards Lifesciences first entered the market. We expect this growth to continue at a moderate pace as indications expand to cover a broader patient population. In addition, competitor Boston Scientific Corporation recently exited the TAVR market, which provides incremental market share opportunity for Edwards Lifesciences. A skilled surgeon surrounded by a team of medical professionals performing a Transcatheter Heart Valve Replacement. Edwards Lifesciences Corporation (NYSE:EW) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 63 hedge fund portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the end of the first quarter, which was 67 in the previous quarter. Edwards Lifesciences Corporation (NYSE: EW) reported total sales of $1.53 billion in Q2 2025, reflecting a growth of 10.6%, which exceeded expectations. While we acknowledge the potential of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we discussed Edwards Lifesciences Corporation (NYSE:EW) and shared Jim Cramer's latest thoughts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store